1. Moscow Declaration to End TB; First WHO global ministerial conference on ending TB in the sustainable development era: a multisectoral response. Geneva: World Health Organization and the Ministry of Health of the Russian Federation; 2017 (https://www.who.int/tb/features_archive/Moscow_Declaration_to_End_TB_final_ENGLISH.pdf?ua=1, accessed 20 December 2019).
2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019.
3. Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis. 2014;6(1).
4. Sustainable development goals [website]. New York: United Nations; (https://sustainabledevelopment.un.org/topics/sustainabledevelopmentgoals, accessed 20 December 2019).
5. Uplekar M, Weil D, Lönnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new End TB strategy. Lancet. 2015;385(9979):1799–801. https://www.ncbi.nlm.nih.gov/pubmed/25814376. accessed 20 December 2019).
6. World Health Organization: Global Tuberculosis Report 2018. 2018. Available from https://www.who.int/tb/publications/global_report/gtbr2018_main_text_28Feb2019.pdf?ua1. accessed 20 December 2019.
7. Beauté J, Dara M, Pd C, Ehsani S, Gozalov O, Hovanesyan A, Ködmön C, Molnarova B, Boom M, van der Werf M. Tuberculosis surveillance and monitoring in Europe 2017; 2017.
8. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis. 1992;73(6):311–21.
9. Reid A, et al., “Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration,” Lancet Infect Dis., vol. 6, pp. 483 – 95, 2006.
10. WHO. “Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings,” vol. 3, 2010.
11. MOH. “National comprehensive HIV care and treatment training manual for health providers,” Ethiopia, 2014.
12. Joint United. Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2017.
13. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001270.
14. Curran A, Falco V, Pahissa A, Ribera E. Management of tuberculosis in HIV-infected patients. AIDS Rev. 2012;14:231–46.
15. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697–706.
16. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–81.
17. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365: 1482–1491. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, et al. (2012) Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 60: 377–383.
18. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy in the control of HIV associated tuberculosis in resource-limited settings. Clinics in Chest Medicine. 2009.
19.Middelkoop K, Wood R, Myer L, Whitelaw A, Kaplan g, McIntyre j, Bekker LG Widespread ART is associated with decline in TB prevalence. 5th IAS conference on HIV Pathogenesis, Prevention and Treatment. Cape Town, South Africa; 2009.
20. Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2008 Nov 30;22(18):2527–33.
21. Centers for Diseases control and prevention (CDC). Global HIV & Tuberculosis Ethiopia Country Profile available at https://www.cdc.gov/globalhivtb/where-we-work/ethiopia/ethiopia.html. In.; last reviewed: August 29, 2019. Accessed December 20, 2019.
22. Alene KA, Nega A, Taye BW. Incidence and predictors of tuberculosis among adult people living with HIV at the university of Gondar referral hospital, northwest Ethiopia. BMC infectious disease. 2013;13:292.
23. Henok B, Mesfin K, Aman Y, Girum T. Incidence and Predictors of Tuberculosis among Adult PLWHA at Public Health Facilities of Hawassa City. International Journal of Public Health Science (IJPHS). 2017;6:3.
24. Demeke G, Aklilu E, Markos N, Setegn E, Belay T. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. BMC Infect Dis. 2019;19:405.
25. Belisty T, Getiye D, Nakachew M, Mamaru W, Yitbarek T, Pammla P, et al. Incidence and predictors of tuberculosis among HIV-positive adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: a retrospective record review. BMC Public Health. 2019;19:1566.
26. Girum T, Abebaw W, Abdulsemed W. Trend of HIV/AIDS for the last 26 Years and Predicting Achievement of the 90-90-90 HIV Prevention Targets by 2020 in Ethiopia: A Time Series Analysis. BMC infectious disease. 2018;18:320.
27. Mahlet S, Teferi G, Girmay M, Dawit A. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/ AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study. BMC Infect Dis. 2017;17:5.